Rsv Bronchiolitis
Pediatric RSV Prevention: Critical Insights on Immunoprophylaxis
This activity is supported by an educational grant from Sanofi US.
Pediatric RSV Prevention: Advances in Disease State, Immunization, and Interprofessional Care
This activity is supported by an educational grant from Sanofi US.
Updates in Preventing Pediatric RSV: Rapid Response From IDWeek
This activity is supported by an educational grant from Sanofi US.
Preventing Pediatric RSV: Latest Strategies in Immunoprophylaxis
This activity is supported by an educational grant from Sanofi US.
Pediatric RSV Prevention – Unlocking New Insights
This activity is supported by an educational grant from Sanofi US.
More real-world evidence shows nirsevimab protects infants against RSV
The monoclonal antibody nirsevimab reduced the risk that infants would be hospitalized for respiratory syncytial virus-associated bronchiolitis, according to a study published Wednesday in The New England Journal of Medicine.
Preventing RSV in Pediatric Patients: A Wheel of Knowledge Challenge!
This activity is supported by an educational grant from Sanofi US.
Prevalence of RSV bronchiolitis in hospitalized infants in U.S. increased in recent years
Among U.S. infants hospitalized with respiratory syncytial virus bronchiolitis, the overall prevalence, presence of complex chronic conditions and invasive mechanical ventilation use increased from 1997 to 2016, researchers reported.